Vitrafy Targets US Health Market as Shareholders Back Placement Facility
VFY: $2.65 +3.92% · MC: $165M
Vitrafy Life Sciences is focusing its direct commercial efforts on US human health while pursuing animal reproduction through its partnership with IMV Technologies. The company expects short-term costs to rise as it invests in validation, manufacturing and delivery of initial medical devices, and held approximately $38 million in cash and term deposits at the end of September. At its annual meeting, shareholders approved an additional placement facility and performance rights for CEO Brent Owens, and elected Jeannette Joughin and re-elected Kate Munnings as directors.

Comments